With the rapid development of large-scale genome−sequencing technologies, numerous molecular biomarkers for GBM have been reported in the literature, including IDH 1/2 mutation, MGMT promoter methylation status, TERT promoter mutations, B-Raf proto-oncogene (BRAF) mutations, ATRX mutations, EGFR mutations, and 1p/19q codeletion (Smith et al., 2000; Liu et al., 2012; Chan et al., 2015; Bell et al., 2018). The gene discussed is BRAF; the disease is glioblastoma.